Orion Oyj
ORION CORPORATION STOCK EXCHANGE RELEASE 25 MARCH 2021 at 5.55 p.m. EET
Orion Corporation: Organising meeting of the Board of Directors
In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Timo Maasilta as Vice Chairman.
The compositions of the Board committees were decided to be as follows:
Personnel and Remuneration Committee:
Mikael Silvennoinen, Chairman
Veli-Matti Mattila
Hilpi Rautelin
Audit Committee:
Ari Lehtoranta, Chairman
Kari Jussi Aho
Pia Kalsta
Eija Ronkainen
R&D Committee:
Hilpi Rautelin, Chairman
Kari Jussi Aho
Pia Kalsta
Ari Lehtoranta
Timo Maasilta
Veli-Matti Mattila
Eija Ronkainen
Mikael Silvennoinen
The name of the Remuneration Committee has been changed to the Personnel and Remuneration Committee.
The Company also has a Nomination Committee, the election of which was announced in a Stock Exchange Release on 21 October 2020.
All members of the Board of Directors have been assessed to be independent of the company and its significant shareholders.
Orion Corporation
Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Contact person:
Olli Huotari, Senior Vice President, Corporate Functions
Phone +358 50 966 3054
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
FLSmidth A/S9.7.2025 08:41:33 CEST | Press release
Correction to Company Announcement no. 15-2025: Transactions under share buy-back programme
Syensqo SA9.7.2025 08:30:00 CEST | Press release
Syensqo - Participation notification by BlackRock Inc.
Sparekassen Sjælland-Fyn A/S9.7.2025 08:13:26 CEST | Pressemeddelelse
SJF Bank opjusterer forventningerne til resultatet for 2025
Ekopak N.V.9.7.2025 08:10:24 CEST | Press release
Ekopak appoints Jean-Baptiste De Cuyper as new CEO
Purespring Therapeutics9.7.2025 08:00:00 CEST | Press release
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom